New findings highlighted a pair of blood signals that can diverge early and refine liver cancer therapy response assessment in hepatocellular carcinoma. The premise is that the first treatment weeks often fall into a diagnostic gray zone when tumors are too large for surgery and clinicians wait for the first scan. By tracking blood-based dynamics early in the treatment course, the study frames a potential shift toward earlier, more actionable risk stratification for combinations of immunotherapy and targeted agents used in unresectable settings. The development adds to the broader oncology push to replace waiting for imaging with earlier, less invasive readouts that can guide therapy decisions sooner.